NO972896L - Medisinsk artikkel - Google Patents

Medisinsk artikkel

Info

Publication number: NO972896L
Authority: NO; Norway
Prior art keywords: catheter; medical article; article according; therapeutically acceptable; antibacterial agent
Prior art date: 1996-06-21

Application number

NO972896A

Other languages

English (en)

Norwegian (no)

Other versions

NO972896D0 (no

Inventor

Thomas Stuart Jackson Elliott

Original Assignee

Boc Group Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-21

Filing date

1997-06-20

Publication date

1997-12-22

1997-06-20 Application filed by Boc Group Plc filed Critical Boc Group Plc

1997-06-20 Publication of NO972896D0 publication Critical patent/NO972896D0/no

1997-12-22 Publication of NO972896L publication Critical patent/NO972896L/no

Links

239000003242 anti bacterial agent Substances 0.000 claims description 57
239000000243 solution Substances 0.000 claims description 24
229940024606 amino acid Drugs 0.000 claims description 22
235000001014 amino acid Nutrition 0.000 claims description 22
150000001413 amino acids Chemical class 0.000 claims description 22
239000012530 fluid Substances 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 18
229920003023 plastic Polymers 0.000 claims description 16
239000004033 plastic Substances 0.000 claims description 16
239000011248 coating agent Substances 0.000 claims description 10
238000000576 coating method Methods 0.000 claims description 10
239000004475 Arginine Substances 0.000 claims description 9
239000002253 acid Chemical class 0.000 claims description 9
230000000844 anti-bacterial effect Effects 0.000 claims description 9
229960003121 arginine Drugs 0.000 claims description 9
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
150000007524 organic acids Chemical class 0.000 claims description 8
230000007935 neutral effect Effects 0.000 claims description 7
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
210000001124 body fluid Anatomy 0.000 claims description 6
239000010839 body fluid Substances 0.000 claims description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
241001465754 Metazoa Species 0.000 claims description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
239000000463 material Substances 0.000 claims description 4
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
230000001050 lubricating effect Effects 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
150000003242 quaternary ammonium salts Chemical class 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 3
210000003462 vein Anatomy 0.000 claims description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
239000004471 Glycine Substances 0.000 claims description 2
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 2
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
239000004472 Lysine Substances 0.000 claims description 2
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
239000004473 Threonine Substances 0.000 claims description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
229960003767 alanine Drugs 0.000 claims description 2
235000004279 alanine Nutrition 0.000 claims description 2
150000001450 anions Chemical class 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims description 2
229960001230 asparagine Drugs 0.000 claims description 2
235000009582 asparagine Nutrition 0.000 claims description 2
150000001805 chlorine compounds Chemical group 0.000 claims description 2
235000015165 citric acid Nutrition 0.000 claims description 2
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 2
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
229960002743 glutamine Drugs 0.000 claims description 2
229960002449 glycine Drugs 0.000 claims description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 2
229960002591 hydroxyproline Drugs 0.000 claims description 2
229960000310 isoleucine Drugs 0.000 claims description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
229960003136 leucine Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
229930182817 methionine Natural products 0.000 claims description 2
229960004452 methionine Drugs 0.000 claims description 2
229960003104 ornithine Drugs 0.000 claims description 2
235000006408 oxalic acid Nutrition 0.000 claims description 2
229960005190 phenylalanine Drugs 0.000 claims description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
229960002429 proline Drugs 0.000 claims description 2
229960001153 serine Drugs 0.000 claims description 2
239000011975 tartaric acid Chemical class 0.000 claims description 2
235000002906 tartaric acid Nutrition 0.000 claims description 2
229960002898 threonine Drugs 0.000 claims description 2
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 2
229960004799 tryptophan Drugs 0.000 claims description 2
229960004441 tyrosine Drugs 0.000 claims description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
229960004295 valine Drugs 0.000 claims description 2
239000004474 valine Substances 0.000 claims description 2
CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical class CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims 3
150000001412 amines Chemical group 0.000 claims 2
BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 claims 1
150000001242 acetic acid derivatives Chemical class 0.000 claims 1
238000000605 extraction Methods 0.000 claims 1
238000002156 mixing Methods 0.000 claims 1
229960000686 benzalkonium chloride Drugs 0.000 description 41
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 41
238000002474 experimental method Methods 0.000 description 17
KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 15
241000589517 Pseudomonas aeruginosa Species 0.000 description 13
-1 benzalkonium halide Chemical class 0.000 description 13
230000000694 effects Effects 0.000 description 13
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 12
229930064664 L-arginine Natural products 0.000 description 12
235000014852 L-arginine Nutrition 0.000 description 12
244000005700 microbiome Species 0.000 description 11
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
238000011534 incubation Methods 0.000 description 9
239000000203 mixture Substances 0.000 description 9
229920002635 polyurethane Polymers 0.000 description 9
239000004814 polyurethane Substances 0.000 description 9
235000009697 arginine Nutrition 0.000 description 8
239000007788 liquid Substances 0.000 description 8
235000015097 nutrients Nutrition 0.000 description 8
KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 7
241000894006 Bacteria Species 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
239000001267 polyvinylpyrrolidone Substances 0.000 description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
229960003589 arginine hydrochloride Drugs 0.000 description 6
238000005470 impregnation Methods 0.000 description 6
238000000338 in vitro Methods 0.000 description 5
238000000034 method Methods 0.000 description 5
UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 4
230000000845 anti-microbial effect Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 4
229920001519 homopolymer Polymers 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
206010040047 Sepsis Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
229960001716 benzalkonium Drugs 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
150000004820 halides Chemical class 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000002904 solvent Substances 0.000 description 3
DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 3
229920002554 vinyl polymer Polymers 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010069802 Device related sepsis Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical group CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
241000191940 Staphylococcus Species 0.000 description 2
XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
125000005501 benzalkonium group Chemical class 0.000 description 2
230000009172 bursting Effects 0.000 description 2
WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000007598 dipping method Methods 0.000 description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
229940116333 ethyl lactate Drugs 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
238000013048 microbiological method Methods 0.000 description 2
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229940112041 peripherally acting muscle relaxants other quaternary ammonium compound in atc Drugs 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
229920000909 polytetrahydrofuran Polymers 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical compound C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
208000032840 Catheter-Related Infections Diseases 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
239000004433 Thermoplastic polyurethane Substances 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960003872 benzethonium Drugs 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
229940115457 cetyldimethylethylammonium bromide Drugs 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000001979 cystine lactose electrolyte deficient agar Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
VUFOSBDICLTFMS-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)CC VUFOSBDICLTFMS-UHFFFAOYSA-M 0.000 description 1
238000002637 fluid replacement therapy Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000002642 intravenous therapy Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000002386 leaching Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
244000039328 opportunistic pathogen Species 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229920002803 thermoplastic polyurethane Polymers 0.000 description 1
201000005060 thrombophlebitis Diseases 0.000 description 1
235000021476 total parenteral nutrition Nutrition 0.000 description 1
UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/208—Quaternary ammonium compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
- A61L2300/214—Amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Materials For Medical Uses (AREA)
Apparatus For Disinfection Or Sterilisation (AREA)

NO972896A 1996-06-21 1997-06-20 Medisinsk artikkel NO972896L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9613010.9A GB9613010D0 (en)	1996-06-21	1996-06-21	Medical article

Publications (2)

Publication Number	Publication Date
NO972896D0 NO972896D0 (no)	1997-06-20
NO972896L true NO972896L (no)	1997-12-22

Family

ID=10795659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO972896A NO972896L (no)	1996-06-21	1997-06-20	Medisinsk artikkel

Country Status (8)

Country	Link
EP (1)	EP0818207A3 (de)
JP (1)	JPH1080467A (de)
KR (1)	KR980000485A (de)
AU (1)	AU2614497A (de)
GB (1)	GB9613010D0 (de)
NO (1)	NO972896L (de)
PL (1)	PL320683A1 (de)
SG (1)	SG71026A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8133501B2 (en)	2002-02-08	2012-03-13	Boston Scientific Scimed, Inc.	Implantable or insertable medical devices for controlled drug delivery
US8685427B2 (en)	2002-07-31	2014-04-01	Boston Scientific Scimed, Inc.	Controlled drug delivery
US8920826B2 (en)	2002-07-31	2014-12-30	Boston Scientific Scimed, Inc.	Medical imaging reference devices
US12558335B2 (en)	2019-09-19	2026-02-24	Rls Global Ab	Preparation for removal and/or prevention of an infection associated with Staphylococcus epidermidis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0065884B1 (de) *	1981-05-27	1986-08-20	Unitika Ltd.	Zur Verhinderung einer Harnleiterinfektion geeigneter Urethralkatheter und Verfahren zur Herstellung desselben
US4879135A (en) *	1984-07-23	1989-11-07	University Of Medicine And Dentistry Of New Jersey	Drug bonded prosthesis and process for producing same
US4749585A (en) *	1986-04-11	1988-06-07	University Of Medicine And Dentistry Of New Jersey	Antibiotic bonded prosthesis and process for producing same
DE4216271A1 (de) *	1992-05-16	1993-11-18	Siegel Rolf	Verfahren zur naßchemischen Oberflächenmodifizierung von Formkörpern aus Organopolysiloxanen sowie Verwendung der Verfahrenserzeugnisse
US5504113A (en) *	1994-03-02	1996-04-02	Allergan, Inc.	Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug

1996
- 1996-06-21 GB GBGB9613010.9A patent/GB9613010D0/en active Pending
1997
- 1997-06-17 EP EP97304227A patent/EP0818207A3/de not_active Withdrawn
- 1997-06-18 SG SG1997002090A patent/SG71026A1/en unknown
- 1997-06-19 AU AU26144/97A patent/AU2614497A/en not_active Abandoned
- 1997-06-20 PL PL97320683A patent/PL320683A1/xx unknown
- 1997-06-20 KR KR1019970026001A patent/KR980000485A/ko not_active Withdrawn
- 1997-06-20 NO NO972896A patent/NO972896L/no unknown
- 1997-06-23 JP JP9165928A patent/JPH1080467A/ja active Pending

Also Published As

Publication number	Publication date
AU2614497A (en)	1998-01-08
KR980000485A (ko)	1998-03-30
EP0818207A2 (de)	1998-01-14
PL320683A1 (en)	1997-12-22
EP0818207A3 (de)	1999-06-02
SG71026A1 (en)	2000-03-21
JPH1080467A (ja)	1998-03-31
GB9613010D0 (en)	1996-08-28
NO972896D0 (no)	1997-06-20

Publication	Publication Date	Title
US7314857B2 (en)	2008-01-01	Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
US6589591B1 (en)	2003-07-08	Method for treating medical devices using glycerol and an antimicrobial agent
US7329412B2 (en)	2008-02-12	Antimicrobial medical devices containing chlorhexidine free base and salt
US6224579B1 (en)	2001-05-01	Triclosan and silver compound containing medical devices
CA2897860C (en)	2019-08-20	Devices with anti-thrombogenic and anti-microbial treatment
US6872195B2 (en)	2005-03-29	Chlorhexidine-containing medical devices
Jansen et al.	1992	In-vitro efficacy of a central venous catheter (‘Hydrocath’) loaded with teicoplanin to prevent bacterial colonization
US5516480A (en)	1996-05-14	Bactericidal and/or fungicidal plastic parts for use in the medical field
US20110311602A1 (en)	2011-12-22	Transdermal venous access locking solutions
US9433209B2 (en)	2016-09-06	Transdermal venous access locking solutions
US20080279907A1 (en)	2008-11-13	Antimicrobial medical devices and methods for making and using same
US20140178447A1 (en)	2014-06-26	Reduction of biofilms on medical devices
EP2754413B1 (de)	2019-10-23	Medizingeräte mit Nitroprussid und antimikrobiellen Wirkstoffen
WO2005018701A1 (en)	2005-03-03	Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
EP2968686A1 (de)	2016-01-20	Polymerbeschichtungen mit antimikrobiellen eigenschaften
NO972896L (no)	1997-12-22	Medisinsk artikkel
CA2846891C (en)	2017-10-24	Transdermal venous access locking solutions
EP3411088B1 (de)	2023-06-07	Implantierbare medizinische produkte, verfahren zu deren herstellung und deren verwendung
US9427498B2 (en)	2016-08-30	Syringe treated with transdermal venous access locking solutions and method of treating the syringe
CA2452032C (en)	2007-05-01	Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
Subramanyam et al.	1999	Infection-Resistant Coating
MXPA06006379A (en)	2007-04-20	Gallium inhibits biofilm formation